Nymox Pharmaceutical Corporation (NYMX) News

Nymox Pharmaceutical Corporation (NYMX)

Today's Latest Price: $3.46 USD

0.00 (0.00%)

Updated Jun 1 11:13am

Add NYMX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter NYMX News Items

NYMX News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest NYMX News From Around the Web

Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

If You Had Bought Nymox Pharmaceutical (NASDAQ:NYMX) Shares Five Years Ago You'd Have Made 91%

It hasn't been the best quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shareholders, since the share price...

Yahoo | May 5, 2020

Nymox Announces Important New Patent Developments

HASBROUCK HEIGHTS, N.J., April 21, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international.

Yahoo | April 21, 2020

Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | March 21, 2020

Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology

Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer. This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment. The new publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection ‎Treatment of Grade Group 1 Prostate Cancer: Four Year Results”.

Yahoo | February 24, 2020

Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries. Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.

Yahoo | February 6, 2020

Is Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) CEO Being Overpaid?

The CEO of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is Paul Averback. This report will, first, examine the CEO...

Yahoo | February 5, 2020

Nymox Provides Update on Current Corporate Activities and Milestones

HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate.

Yahoo | January 28, 2020

The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the rep...

Benzinga | January 7, 2020

Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on.

Yahoo | January 6, 2020

Hedge Funds Have Never Been More Bullish On Nymox Pharmaceutical Corporation (NYMX)

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

Yahoo | December 23, 2019

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.765 seconds.